Search

Your search keyword '"Marriott, Heather"' showing total 19 results
Start Over Author "Marriott, Heather"

Refine your results

more »

more »

more »
19 results on '"Marriott, Heather"'

4. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

Author

Neurologen, Projectafdeling ALS, Brain, Neurogenetica, Genetic Risks, Marriott, Heather, Spargo, Thomas P, Al Khleifat, Ahmad, Andersen, Peter M, Başak, Nazli A, Cooper-Knock, Johnathan, Corcia, Philippe, Couratier, Philippe, de Carvalho, Mamede, Drory, Vivian, Gotkine, Marc, Landers, John E, McLaughlin, Russell, Pardina, Jesús S Mora, Morrison, Karen E, Pinto, Susana, Shaw, Christopher E, Shaw, Pamela J, Silani, Vincenzo, Ticozzi, Nicola, van Damme, Philip, van den Berg, Leonard H, Vourc'h, Patrick, Weber, Markus, Veldink, Jan H, Dobson, Richard J, Schwab, Patrick, Al-Chalabi, Ammar, Iacoangeli, Alfredo, Project MinE ALS Sequencing Consortium, Neurologen, Projectafdeling ALS, Brain, Neurogenetica, Genetic Risks, Marriott, Heather, Spargo, Thomas P, Al Khleifat, Ahmad, Andersen, Peter M, Başak, Nazli A, Cooper-Knock, Johnathan, Corcia, Philippe, Couratier, Philippe, de Carvalho, Mamede, Drory, Vivian, Gotkine, Marc, Landers, John E, McLaughlin, Russell, Pardina, Jesús S Mora, Morrison, Karen E, Pinto, Susana, Shaw, Christopher E, Shaw, Pamela J, Silani, Vincenzo, Ticozzi, Nicola, van Damme, Philip, van den Berg, Leonard H, Vourc'h, Patrick, Weber, Markus, Veldink, Jan H, Dobson, Richard J, Schwab, Patrick, Al-Chalabi, Ammar, Iacoangeli, Alfredo, and Project MinE ALS Sequencing Consortium

Published
2024

5. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS

Author

Marriott, Heather, Spargo, Thomas P., Al Khleifat, Ahmad, Andersen, Peter M., Başak, Nazli A., Cooper-Knock, Johnathan, Corcia, Philippe, Couratier, Philippe, de Carvalho, Mamede, Drory, Vivian, Gotkine, Marc, Landers, John E., McLaughlin, Russell, Pardina, Jesús S. Mora, Morrison, Karen E., Pinto, Susana, Shaw, Christopher E., Shaw, Pamela J., Silani, Vincenzo, Ticozzi, Nicola, van Damme, Philip, van den Berg, Leonard H., Vourc'h, Patrick, Weber, Markus, Veldink, Jan H., Dobson, Richard J., Schwab, Patrick, Al-Chalabi, Ammar, Iacoangeli, Alfredo, Marriott, Heather, Spargo, Thomas P., Al Khleifat, Ahmad, Andersen, Peter M., Başak, Nazli A., Cooper-Knock, Johnathan, Corcia, Philippe, Couratier, Philippe, de Carvalho, Mamede, Drory, Vivian, Gotkine, Marc, Landers, John E., McLaughlin, Russell, Pardina, Jesús S. Mora, Morrison, Karen E., Pinto, Susana, Shaw, Christopher E., Shaw, Pamela J., Silani, Vincenzo, Ticozzi, Nicola, van Damme, Philip, van den Berg, Leonard H., Vourc'h, Patrick, Weber, Markus, Veldink, Jan H., Dobson, Richard J., Schwab, Patrick, Al-Chalabi, Ammar, and Iacoangeli, Alfredo

Abstract

Objective: Neurofilament heavy-chain gene (NEFH) variants are associated with multiple neurodegenerative diseases, however, their relationship with ALS has not been robustly explored. Still, NEFH is commonly included in genetic screening panels worldwide. We therefore aimed to determine if NEFH variants modify ALS risk. Methods: Genetic data of 11,130 people with ALS and 7,416 controls from the literature and Project MinE were analysed. We performed meta-analyses of published case–control studies reporting NEFH variants, and variant analysis of NEFH in Project MinE whole-genome sequencing data. Results: Fixed-effects meta-analysis found that rare (MAF <1%) missense variants in the tail domain of NEFH increase ALS risk (OR 4.55, 95% CI 2.13–9.71, p < 0.0001). In Project MinE, ultrarare NEFH variants increased ALS risk (OR 1.37 95% CI 1.14–1.63, p = 0.0007), with rod domain variants (mostly intronic) appearing to drive the association (OR 1.45 95% CI 1.18–1.77, pMadsen–Browning = 0.0007, pSKAT-O = 0.003). While in the tail domain, ultrarare (MAF <0.1%) pathogenic missense variants were also associated with higher risk of ALS (OR 1.94, 95% CI 0.86–4.37, pMadsen–Browning = 0.039), supporting the meta-analysis results. Finally, several tail in-frame deletions were also found to affect disease risk, however, both protective and pathogenic deletions were found in this domain, highlighting an intricated architecture that requires further investigation. Interpretation: We showed that NEFH tail missense and in-frame deletion variants, and intronic rod variants are risk factors for ALS. However, they are not variants of large effect, and their functional impact needs to be clarified in further studies. Therefore, their inclusion in routine genetic screening panels should be reconsidered.

Published
2024
Full Text
View/download PDF

6. Transcriptomics Analyses of ALS Post-mortem Motor Cortex highlight alteration and potential biomarkers in the Neuropeptide Signalling pathway

Author

Kabiljo, Renata, primary, Marriott, Heather, additional, Hunt, Guy, additional, Pfaff, Abigail, additional, Al Khleifat, Ahmad, additional, Adey, Brett Nicholas, additional, Jones, Ashley, additional, Troakes, Claire, additional, Quinn, John, additional, Dobson, Richard, additional, Koks, Sulev, additional, Al Chalabi, Ammar, additional, and iacoangeli, alfredo, additional

Published
2023
Full Text
View/download PDF

7. Unsupervised machine learning identifies distinct molecular and phenotypic ALS subtypes in post-mortem motor cortex and blood expression data

Author

Marriott, Heather, primary, kabiljo, Renata, additional, Hunt, Guy P, additional, Al Khleifat, Ahmad, additional, Jones, Ashley R, additional, Troakes, Claire, additional, Pfaff, Abigail, additional, Quinn, John, additional, Koks, Sulev, additional, Dobson, Richard, additional, Schwab, Patrick, additional, Al-Chalabi, Ammar, additional, and iacoangeli, alfredo, additional

Published
2023
Full Text
View/download PDF

9. Clinical testing panels for ALS : global distribution, consistency, and challenges

Author

Dilliott, Allison A., Al Nasser, Ahmad, Elnagheeb, Marwa, Fifita, Jennifer, Henden, Lyndal, Keseler, Ingrid M., Lenz, Steven, Marriott, Heather, Mccann, Emily, Mesaros, Maysen, Opie-Martin, Sarah, Owens, Emma, Palus, Brooke, Ross, Justyne, Wang, Zhanjun, White, Hannah, Al-Chalabi, Ammar, Andersen, Peter M., Benatar, Michael, Blair, Ian, Cooper-Knock, Johnathan, Harrington, Elizabeth A., Heckmann, Jeannine, Landers, John, Moreno, Cristiane, Nel, Melissa, Rampersaud, Evadnie, Roggenbuck, Jennifer, Rouleau, Guy, Traynor, Bryan, Van Blitterswijk, Marka, Van Rheenen, Wouter, Veldink, Jan, Weishaupt, Jochen, Drury, Luke, Harms, Matthew B., Farhan, Sali M. K., Dilliott, Allison A., Al Nasser, Ahmad, Elnagheeb, Marwa, Fifita, Jennifer, Henden, Lyndal, Keseler, Ingrid M., Lenz, Steven, Marriott, Heather, Mccann, Emily, Mesaros, Maysen, Opie-Martin, Sarah, Owens, Emma, Palus, Brooke, Ross, Justyne, Wang, Zhanjun, White, Hannah, Al-Chalabi, Ammar, Andersen, Peter M., Benatar, Michael, Blair, Ian, Cooper-Knock, Johnathan, Harrington, Elizabeth A., Heckmann, Jeannine, Landers, John, Moreno, Cristiane, Nel, Melissa, Rampersaud, Evadnie, Roggenbuck, Jennifer, Rouleau, Guy, Traynor, Bryan, Van Blitterswijk, Marka, Van Rheenen, Wouter, Veldink, Jan, Weishaupt, Jochen, Drury, Luke, Harms, Matthew B., and Farhan, Sali M. K.

Abstract

Objective: In 2021, the Clinical Genome Resource (ClinGen) amyotrophic lateral sclerosis (ALS) spectrum disorders Gene Curation Expert Panel (GCEP) was established to evaluate the strength of evidence for genes previously reported to be associated with ALS. Through this endeavor, we will provide standardized guidance to laboratories on which genes should be included in clinical genetic testing panels for ALS. In this manuscript, we aimed to assess the heterogeneity in the current global landscape of clinical genetic testing for ALS. Methods: We reviewed the National Institutes of Health (NIH) Genetic Testing Registry (GTR) and members of the ALS GCEP to source frequently used testing panels and compare the genes included on the tests. Results: 14 clinical panels specific to ALS from 14 laboratories covered 4 to 54 genes. All panels report on ANG, SOD1, TARDBP, and VAPB; 50% included or offered the option of including C9orf72 hexanucleotide repeat expansion (HRE) analysis. Of the 91 genes included in at least one of the panels, 40 (44.0%) were included on only a single panel. We could not find a direct link to ALS in the literature for 14 (15.4%) included genes. Conclusions: The variability across the surveyed clinical genetic panels is concerning due to the possibility of reduced diagnostic yields in clinical practice and risk of a missed diagnoses for patients. Our results highlight the necessity for consensus regarding the appropriateness of gene inclusions in clinical genetic ALS tests to improve its application for patients living with ALS and their families.

Published
2023
Full Text
View/download PDF

10. Clinical testing panels for ALS: global distribution, consistency, and challenges

Author

Dilliott, Allison A., primary, Al Nasser, Ahmad, additional, Elnageeb, Marwa, additional, Fifita, Jennifer, additional, Henden, Lyndal, additional, Keseler, Ingrid M., additional, Lenz, Steven, additional, Marriott, Heather, additional, McCann, Emily, additional, Mesaros, Maysen, additional, Opie-Martin, Sarah, additional, Owens, Emma, additional, Palus, Brooke, additional, Ross, Justyne, additional, Wang, Zhanjun, additional, White, Hannah, additional, Al-Chalabi, Ammar, additional, Andersen, Peter M., additional, Benatar, Michael, additional, Blair, Ian, additional, Cooper-Knock, Johnathan, additional, Drury, Luke, additional, Harrington, Elizabeth, additional, Heckmann, Jeannine, additional, Landers, John, additional, Moreno, Cristiane, additional, Nel, Melissa, additional, Rampersaud, Evadnie, additional, Roggenbuck, Jennifer, additional, Rouleau, Guy, additional, Traynor, Bryan, additional, van Blitterswijk, Marka, additional, van Rheenen, Wouter, additional, Veldink, Jan, additional, Weishaupt, Jochen, additional, Harms, Matthew B., additional, and Farhan, Sali M.K., additional

Published
2022
Full Text
View/download PDF

13. Your letters.

Author

Merryfield, Karen, Leela, Hatherall, Margaret, Ruth, Carmarthen, Geri Mottram, Lynne, Smith, Linda, Katie, Bullis, Terry, Wilson, Ronnie, Passey, Louise, Lodge, Claire, Marriott, Heather, Lugnani, Sara, Skyrme, Rhian, Smith, Betty, and Shimshek, Anna

Published
2017

17. Sex and intimacy.

Author

Marriott, Heather

Subjects
MAN-woman relationships
Abstract

Discusses the various pressures that can cause problems in long-term relationships. Importance of communication in relationships; How to keep your sexual relationships happy; Examples of problems which occur in long-term relationships; Stories on couples and their experiences. INSETS: Lisa Ellis.;Rowena Madison..

Published
1997

18. Mutations in the tail and rod domains of the neurofilament heavy-chain gene increase the risk of ALS.

Author

Marriott H, Spargo TP, Al Khleifat A, Andersen PM, Başak NA, Cooper-Knock J, Corcia P, Couratier P, de Carvalho M, Drory V, Gotkine M, Landers JE, McLaughlin R, Pardina JSM, Morrison KE, Pinto S, Shaw CE, Shaw PJ, Silani V, Ticozzi N, van Damme P, van den Berg LH, Vourc'h P, Weber M, Veldink JH, Dobson RJ, Schwab P, Al-Chalabi A, and Iacoangeli A

Subjects
Humans, Genetic Predisposition to Disease genetics, Mutation, Mutation, Missense, Protein Domains genetics, Amyotrophic Lateral Sclerosis genetics, Amyotrophic Lateral Sclerosis epidemiology, Neurofilament Proteins genetics
Abstract

Objective: Neurofilament heavy-chain gene (NEFH) variants are associated with multiple neurodegenerative diseases, however, their relationship with ALS has not been robustly explored. Still, NEFH is commonly included in genetic screening panels worldwide. We therefore aimed to determine if NEFH variants modify ALS risk., Methods: Genetic data of 11,130 people with ALS and 7,416 controls from the literature and Project MinE were analysed. We performed meta-analyses of published case-control studies reporting NEFH variants, and variant analysis of NEFH in Project MinE whole-genome sequencing data., Results: Fixed-effects meta-analysis found that rare (MAF <1%) missense variants in the tail domain of NEFH increase ALS risk (OR 4.55, 95% CI 2.13-9.71, p < 0.0001). In Project MinE, ultrarare NEFH variants increased ALS risk (OR 1.37 95% CI 1.14-1.63, p = 0.0007), with rod domain variants (mostly intronic) appearing to drive the association (OR 1.45 95% CI 1.18-1.77, p Madsen-Browning  = 0.0007, p SKAT-O  = 0.003). While in the tail domain, ultrarare (MAF <0.1%) pathogenic missense variants were also associated with higher risk of ALS (OR 1.94, 95% CI 0.86-4.37, p Madsen-Browning  = 0.039), supporting the meta-analysis results. Finally, several tail in-frame deletions were also found to affect disease risk, however, both protective and pathogenic deletions were found in this domain, highlighting an intricate architecture that requires further investigation., Interpretation: We showed that NEFH tail missense and in-frame deletion variants, and intronic rod variants are risk factors for ALS. However, they are not variants of large effect, and their functional impact needs to be clarified in further studies. Therefore, their inclusion in routine genetic screening panels should be reconsidered., (© 2024 The Author(s). Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)

Published
2024
Full Text
View/download PDF

19. Clinical testing panels for ALS: global distribution, consistency, and challenges.

Author

Dilliott AA, Al Nasser A, Elnagheeb M, Fifita J, Henden L, Keseler IM, Lenz S, Marriott H, Mccann E, Mesaros M, Opie-Martin S, Owens E, Palus B, Ross J, Wang Z, White H, Al-Chalabi A, Andersen PM, Benatar M, Blair I, Cooper-Knock J, Harrington EA, Heckmann J, Landers J, Moreno C, Nel M, Rampersaud E, Roggenbuck J, Rouleau G, Traynor B, Van Blitterswijk M, Van Rheenen W, Veldink J, Weishaupt J, Drury L, Harms MB, and Farhan SMK

Subjects
Humans, Mutation, Genetic Testing methods, C9orf72 Protein genetics, Amyotrophic Lateral Sclerosis diagnosis, Amyotrophic Lateral Sclerosis genetics
Abstract

Objective : In 2021, the Clinical Genome Resource (ClinGen) amyotrophic lateral sclerosis (ALS) spectrum disorders Gene Curation Expert Panel (GCEP) was established to evaluate the strength of evidence for genes previously reported to be associated with ALS. Through this endeavor, we will provide standardized guidance to laboratories on which genes should be included in clinical genetic testing panels for ALS. In this manuscript, we aimed to assess the heterogeneity in the current global landscape of clinical genetic testing for ALS. Methods : We reviewed the National Institutes of Health (NIH) Genetic Testing Registry (GTR) and members of the ALS GCEP to source frequently used testing panels and compare the genes included on the tests. Results : 14 clinical panels specific to ALS from 14 laboratories covered 4 to 54 genes. All panels report on ANG , SOD1 , TARDBP , and VAPB ; 50% included or offered the option of including C9orf72 hexanucleotide repeat expansion (HRE) analysis. Of the 91 genes included in at least one of the panels, 40 (44.0%) were included on only a single panel. We could not find a direct link to ALS in the literature for 14 (15.4%) included genes. Conclusions : The variability across the surveyed clinical genetic panels is concerning due to the possibility of reduced diagnostic yields in clinical practice and risk of a missed diagnoses for patients. Our results highlight the necessity for consensus regarding the appropriateness of gene inclusions in clinical genetic ALS tests to improve its application for patients living with ALS and their families.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results